Literature DB >> 14993385

Protein origami: therapeutic rescue of misfolded gene products.

P Michael Conn1, Alfredo Leaños-Miranda, Jo Ann Janovick.   

Abstract

Receptor mutations that elicit loss of function are sometimes equated with defects that ablate receptor-ligand binding or receptor-effector interactions. Similarly, mutationally defective enzymes and ion channels are often viewed as compromised in substrate or ion recognition, respectively. Recent observations, however, suggest that an alternate mechanism may be surprisingly common, namely, that mutations in structural genes may not interfere with the inherent functionality of the affected protein, but nevertheless cause disease by preventing the cell's trafficking machinery from placing the affected protein at the appropriate subcellular compartment (e.g., at the cell membrane). Accordingly, therapies may be devised to ensure the placement of receptors (or other proteins) at locations where they can support cell function.

Mesh:

Substances:

Year:  2002        PMID: 14993385     DOI: 10.1124/mi.2.5.308

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  21 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Authors:  Jo Ann Janovick; Irina D Pogozheva; Henry I Mosberg; Anda Cornea; P Michael Conn
Journal:  Mol Endocrinol       Date:  2012-05-17

3.  Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.

Authors:  Jo Ann Janovick; Shaun P Brothers; Anda Cornea; Eugene Bush; Mark T Goulet; Wallace T Ashton; Daryl R Sauer; Fortuna Haviv; Jonathan Greer; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2007-05-03       Impact factor: 4.102

Review 4.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease.

Authors:  P Michael Conn; Jo Ann Janovick
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

Review 5.  Assay strategies for identification of therapeutic leads that target protein trafficking.

Authors:  P Michael Conn; Timothy P Spicer; Louis Scampavia; Jo Ann Janovick
Journal:  Trends Pharmacol Sci       Date:  2015-06-08       Impact factor: 14.819

Review 6.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 7.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

8.  Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor.

Authors:  Rodrigo Ayala Yáñez; P Michael Conn
Journal:  Cell Biochem Funct       Date:  2010-01       Impact factor: 3.685

9.  Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine.

Authors:  Jo Ann Janovick; Guadalupe Maya-Núñez; Alfredo Ulloa-Aguirre; Ilpo T Huhtaniemi; James A Dias; Pieter Verbost; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2008-09-20       Impact factor: 4.102

10.  Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system.

Authors:  Alejandro Cabrera-Wrooman; Jo Ann Janovick; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-07-24       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.